EGFR and non-small cell lung carcinoma: Intriguingly, we found that NSCLC patients with co‐occurring alterations of EGFR and other driver genes have higher TMB levels and longer OS than patients with a single EGFR alteration after immunotherapy, and similar results were found between patients with multiple driver gene alterations and single alteration in eight driver genes.